newsfilter
← Latest News
PR Newswire·

Data from Medivir's MIV-818 phase 1b study to be presented at the ESMO Congress

HUDDINGE, Aug. 5, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarc